|Bid||0.00 x N/A|
|Ask||0.00 x N/A|
|Day's range||89.12 - 89.48|
|52-week range||89.12 - 89.48|
|Beta (5Y monthly)||0.36|
|PE ratio (TTM)||0.16|
|Earnings date||01 Aug 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
RAHWAY, N.J. & NUTLEY, N.J., May 25, 2023--KEYTRUDA® Plus LENVIMA® Demonstrates Long-Term, Durable Survival Benefit Versus Sunitinib as First-Line Treatment for Patients With Advanced RCC
RAHWAY, N.J., May 23, 2023--Merck Announces Third-Quarter 2023 Dividend
Hennion & Walsh CIO Kevin Mahn joins Yahoo Finance Live to discuss the state of the consumer amid retail earnings, Target Q1 earnings, Walmart earnings preview, Fed rate hikes, inflation, and the impact on consumer spending.
RAHWAY, N.J., May 15, 2023--Merck ASCO Curtain Raiser
Investors are gearing up for an announcement on UK interest rates which is due at noon.
RAHWAY, N.J., May 03, 2023--Merck to Participate in Bank of America Securities 2023 Healthcare Conference
RAHWAY, N.J., April 28, 2023--Update on FDA Advisory Committee Vote on LYNPARZA Plus Abiraterone and Prednisone or Prednisolone in First-Line mCRPC
Yahoo Finance’s Anjalee Khemlanin joins the Live show to discuss quarterly earnings for Abbvie, Merck & Company, and Biogen, the headwinds facing drugmakers, and what they mean for investors watching the pharmaceuticals space.
RAHWAY, N.J., April 27, 2023--Merck Announces First-Quarter 2023 Financial Results
Yahoo Finance Live highlights Prometheus Bioscience's stock performance amid the company's deal with pharmaceutical giant Merck.
Moderna stock plunges following mixed analyst reviews of cancer vaccine data
Yahoo Finance’s Anjalee Khemlani joins the Live show to discuss news that Merck has agreed to acquire biotechnology company Prometheus Biosciences.
RAHWAY, N.J., April 16, 2023--Merck’s KEYTRUDA® Plus Chemotherapy Significantly Improved OS Compared to Chemotherapy Alone in Patients With Advanced or Unresectable BTC
RAHWAY, N.J. & SAN DIEGO, April 16, 2023--Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Prometheus Biosciences, Inc. ("Prometheus") (Nasdaq: RXDX) today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, has agreed to acquire Prometheus for $200.00 per share in cash for a total equity value of approximately $10.8 billion.
RAHWAY, N.J., April 13, 2023--KEYTRUDA KEYNOTE-859 Filing Acceptance
RAHWAY, N.J. & NUTLEY, N.J., April 07, 2023--Merck and Eisai Provide Update on Phase 3 Trials of KEYTRUDA plus LENVIMA In Certain Patients With Advanced Melanoma and Metastatic Colorectal Cancer
Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that mRNA-4157/V940, an investigational personalized mRNA cancer vaccine, in combination with KEYTRUDA, Merck's anti-PD-1 therapy, has been granted Priority Medicines (PRIME) scheme designation by the European Medicines Agency (EMA) for the adjuvant
RAHWAY, N.J., April 03, 2023--FDA Approves KEYTRUDA in Combination With Padcev for First-Line Treatment of Certain Patients with Locally Advanced or Metastatic Urothelial Cancer
RAHWAY, N.J., March 30, 2023--Merck to Hold First-Quarter 2023 Sales and Earnings Conference Call on April 27
RAHWAY, N.J., March 29, 2023--FDA Converts to Full Approval Indication for KEYTRUDA for Certain Adult and Pediatric Patients With Advanced MSI-H or dMMR Solid Tumors
Yahoo Finance Live’s Brad Smith breaks down how stocks are trading following the opening bell on Wednesday.
RAHWAY, N.J., March 27, 2023--KEYTRUDA® Plus Chemotherapy Significantly Improved PFS Compared to Chemo Alone as 1L Therapy for Advanced or Recurrent Endometrial Carcinoma
RAHWAY, N.J., March 16, 2023--Merck Provides Update from Open-Label Arm of Phase 2 KeyVibe-002 Trial Evaluating MK-7684A in Previously Treated Patients with mNSCLC
RAHWAY, N.J. & KINGSTON, Ontario, March 10, 2023--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and the Canadian Cancer Trials Group (CCTG) today announced that the Phase 2/3 CCTG IND.227/KEYNOTE-483 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with chemotherapy met its primary endpoint of overall survival (OS) for the first-line treatment of patients with unresectable advanced or metastatic malignant pleural mesothelioma. IND.227 was sponsored
RAHWAY, N.J., March 08, 2023--Merck to Present at the Barclays 2023 Global Healthcare Conference